

1st Half (Interim period) of Fiscal 2025 Financial Results

October 27, 2025

Shionogi & Co., Ltd.



SHIONOGI

Agenda

- 01 Overview of 2nd Half (Interim period) FY2025 (P.3-10)**
- 02 FY2025 Forecasts (P.11-16)**
- 03 Domestic and International Business Outlook (P.17-24)**
- 04 Toward the Realization of the 2030 Vision (P.25-36)**
- 05 Shareholder Returns (P.37-38)**

Overview of 2nd Half (Interim period) FY2025 Financial Results



SHIONOGI

2Q Highlights

- **Maintain revenue and operating profit at the same level as the previous year**
 - Stable profit growth in the HIV business and overseas businesses
- **Profit before tax increased, and profit attributable to owners of parent increased slightly**
 - Increased dividend from ViiV reflecting solid progress in the HIV business
- **Progress on key initiatives driving medium to long term growth**
 - HIV business: Expansion of LAI*¹ formulations
 - Acquisition of TORII PHARMACEUTICAL CO., LTD. as a wholly-owned subsidiary*²
 - Ensitrelvir application accepted in the US and Europe

Financial Results

Revenue and operating profit declined year-on-year, but profit before tax and profit attributable to owners of parent were achieved

(Unit: B yen)

	FY2025				FY2024		Y on Y	
	Forecasts		1H results	Achievement (%)	1H results	Change (%)	Change	
	Full year	1H						
Revenue	530.0	233.0	213.0	91.4	214.0	(0.5)	(1.0)	
Operating profit	175.0	82.0	74.8	91.2	75.9	(1.4)	(1.1)	
Profit before tax	222.0	102.0	98.4	96.5	93.8	4.9	4.6	
Profit attributable to owners of parent	180.0	86.0	83.5	97.1	83.1	0.5	0.4	
EBITDA*	196.0	93.0	85.8	92.3	86.7	(1.0)	(0.8)	

Statement of Profit or Loss

(Unit: B yen)

	FY2025		FY2024		Y on Y	
	Forecast		1H Results	Achievement (%)	1H Results	Change (%)
	Full year	1H				Change
Revenue	530.0	233.0	213.0	91.4	214.0	(0.5)
Cost of Sales	16.6	14.2	13.7		14.1	(1.0)
	88.0	33.0	29.3	88.7	30.1	(2.9)
Gross profit	442.0	200.0	183.7	91.9	183.8	(0.1)
SG&A*1, R&D expenses total	49.6	49.8	50.1		49.9	
	263.0	116.0	106.8	92.1	106.7	0.1
SG&A*1	24.7	24.9	25.5		23.3	0.1
	131.0	58.0	54.3	93.7	49.9	8.9
R&D expenses	24.9	24.9	24.6		26.6	4.4
	132.0	58.0	52.4	90.4	56.8	(7.7)
Other income & expenses	(4.0)	(2.0)	(2.2)	107.6	(1.2)	(4.4)
						74.0
Operating profit	33.0	35.2	35.1		35.5	(0.9)
	175.0	82.0	74.8	91.2	75.9	(1.4)
Finance income & costs	47.0	20.0	23.6	118.1	18.0	(1.1)
						31.4
Profit before tax	41.9	43.8	46.2		43.9	5.6
	222.0	102.0	98.4	96.5	93.8	4.9
Profit attributable to owners of parent	180.0	86.0	83.5	97.1	83.1	0.5
						0.4

Main variation factors (Y on Y)

Revenue

- Increase: Royalty income, Overseas subsidiaries /export
- Decrease: Prescription drugs

SG&A

- Increase: Selling-related expenses in US business, PMI costs

R&D expenses


- Decrease: Multiple large-scale clinical trials were conducted in FY2024
 - Ensitrelvir Phase 3 trial
 - S-309309 Phase 2 trial

Finance income & costs

- Increase: Dividends from ViiV
 - Strong sales performance in the HIV franchise

Analysis of Operating Profit Factors (vs. 1H forecast)

Thorough cost management based on the epidemic situation reduces discrepancies with forecasts



Implemented thorough cost optimization across all divisions

• SG&A

- Refined decision-making through strict prioritization
 - > Achieved cost reductions of JPY about 5 billion within two months
- Maintained planned investments essential for growth
 - > Sales-related expenses for the U.S. business

• R&D expenses

- Advanced prioritized R&D investments
 - > Clinical trials for key assets are progressing as planned

Revenue by Segment

(Unit: B yen)

	FY2025		FY2024		Y on Y	
	Forecast Full year	1H	1H Results	Achievement (%)	1H Results	Change(%) Change
Prescription drugs	183.0	62.0	36.8	59.4	47.7	(22.8) (10.9)
Overseas subsidiaries/export	54.9	25.7	30.6	119.2	28.3	8.1 2.3
Shionogi Inc. (US)	22.6	10.9	13.6	124.5	11.2	21.0 2.4
Fetroja	-	-	13.0	-	9.4	39.3 3.7
Shionogi B.V. (EU)	16.9	8.3	9.8	118.4	8.3	18.3 1.5
Fetroja	-	-	7.6	-	6.4	19.1 1.2
Shionogi China	7.0	3.5	3.0	84.9	4.2	(29.2) (1.2)
Others	8.4	3.0	4.3	142.1	4.6	(7.6) (0.4)
Contract manufacturing	13.2	6.5	7.1	109.5	7.8	(8.3) (0.6)
OTC and quasi-drug	18.5	8.9	7.9	88.4	8.2	(3.6) (0.3)
Royalty income	257.9	128.7	129.3	100.5	121.5	6.4 7.8
HIV franchise	244.8	125.8	125.8	100.0	119.6	5.2 6.2
Others	13.1	2.9	3.5	121.0	1.9	84.8 1.6
Others	2.5	1.2	1.2	101.6	0.5	135.4 0.7
Total	530.0	233.0	213.0	91.4	214.0	(0.5) (1.0)

Main variation factors (Y on Y)

Prescription drugs

- Increase: Torii Pharmaceutical*¹
- Decrease: Sales of acute respiratory virus infection treatments
 - Sales of Xocova declined as the outbreak subsided

Overseas subsidiaries/export

- Increase: Sales of cefiderocol (US and Europe)
- Decrease: Sales of China business

Royalty income

- Increase:
 - HIV franchise: Sales generated by ViiV
 - Others: Royalty income from Roche
 - > Influenza outbreaks in China and US

Prescription Drugs in Japan

(Unit: B yen)

			FY2025		FY2024	Y on Y	
	Forecast Full year	Forecast 1H	1H Results	Achievement (%)	1H Results	Change(%)	Change
Acute Respiratory Virus Infection Treatments	85.8	31.0	8.7	28.0	24.9	(65.1)	(16.2)
Quviviq	9.3	1.2	0.4	35.6	-	-	0.4
Symproic	8.1	3.9	2.9	75.0	2.4	23.9	0.6
OxyContin franchise	5.6	2.9	2.3	78.8	2.1	10.7	0.2
Others	74.2	23.0	22.5	97.9	18.4	22.1	4.1
TORII	33.0	3.0	5.5	184.0	-	-	5.5
Total	183.0	62.0	36.8	59.4	47.7	(22.8)	(10.9)

Acute respiratory virus infection treatments

- COVID-19 related product: Xocova
- Influenza franchise: Xofluza, Rapiacta

Results for the 1H of FY 2025 and Future Outlook

Accelerate efforts toward sustainable growth based on 1H results and challenges

	1H results	Challenges
Revenue	Solid progress in the HIV business and overseas businesses • Good progress as a medium to long-term revenue base	Growth in domestic business • Stabilization of acute respiratory infection business • Growth in the QOL disease area*1
Profit	Profit before tax and profit attributable to owners of parent growth were achieved • Actions to manage costs in line with sales	Strengthening company-wide cost management • Timely and effective decision-making

FY2025 Forecasts



SHIONOGI

Revision of Earnings Forecast

Revenue and all profit items are expected to increase compared to the previous year

(Unit: B yen)

	FY2025			FY2024	Y on Y	
	Initial Forecast	Revised Forecast	Revised Amount	Result	Change (%)	Change
Revenue	530.0	500.0	(30.0)	438.3	14.1	61.7
Operating profit	175.0	185.0	10.0	156.6	18.1	28.4
Profit before tax	222.0	232.0	10.0	200.8	15.6	31.2
Profit attributable to owners of parent	180.0	188.0	8.0	170.4	10.3	17.6
EBITDA*1	196.0	206.0	10.0	179.3	14.9	26.7

Assumptions Underlying the Revised Forecast

Revenue forecast revised downward, while all profit metrics revised upward

— Topline —

Upward
revision

Royalty income and overseas subsidiaries/exports

- **Increase in HIV royalty income**
 - Increase in other royalties
 - Strong sales performance of HIV franchise by ViiV
- **Increase in sales at Shionogi Inc., and Shionogi B.V.**
 - Steady sales growth of cefiderocol

Downward
revision

Prescription drugs

Delay in progress of acute respiratory infection treatments

- Revision of forecasts for Xocova, Xofluza, and Quviviq

— Cost management —

SG&A

- Zero-based review following first-half revenue shortfall
- Continued investment in activities for new product launches

R&D

- Review of priorities including JT pharmaceutical pipeline
- Continued investment in key assets as planned

— New business opportunities —

Upward
revision

Growth in other income

- Increase in other revenue

Consolidated Statement of Income

(Unit: B yen)

	FY2025 Forecast Full year			FY2025 Forecast 2H			FY2024	Y on Y	
	Initial Forecast	Revised Forecast	Revised Amount	Forecast (May. 12)	Revised Forecast	Revised Amount	Result	Change(%)	Change
Revenue	530.0	500.0	(30.0)	297.0	287.0	(10.0)	438.3	14.1	61.7
	16.6	16.4		18.5	18.4		14.6		
Cost of Sales	88.0	82.0	(6.0)	55.0	52.7	(2.3)	63.8	28.5	18.2
Gross profit	442.0	418.0	(24.0)	242.0	234.3	(7.7)	374.4	11.6	43.6
SG&A ¹ , R&D expenses total	49.6	48.0		49.5	46.4		49.0		
	263.0	240.0	(23.0)	147.0	133.2	(13.8)	214.7	11.8	25.3
SG&A ^{*1}	24.7	24.0		24.6	22.9		24.2		
	131.0	120.0	(11.0)	73.0	65.7	(7.3)	106.1	13.2	13.9
R&D expenses	24.9	24.0		24.9	23.5		24.8		
	132.0	120.0	(12.0)	74.0	67.6	(6.4)	108.6	10.5	11.4
Other income & Expenses	(4.0)	7.0	11.0	(2.0)	9.2	11.2	(3.2)	-	10.2
Operating profit	33.0	37.0		31.3	38.4		35.7		
	175.0	185.0	10.0	93.0	110.2	17.2	156.6	18.1	28.4
Finance income & costs	47.0	47.0	-	27.0	23.4	(3.6)	44.1	6.5	2.9
Profit before tax	41.9	46.4		40.4	46.6		45.8		
	222.0	232.0	10.0	120.0	133.6	13.6	200.8	15.6	31.2
Profit attributable to owners of parent	180.0	188.0	8.0	94.0	104.5	10.5	170.4	10.3	17.6

Revenue by Business Segment

(Unit: B yen)

	FY2025 Forecast Full year			FY2025 Forecast 2H			FY2024	Y on Y	
	Initial Forecast	Revised Forecast	Revised Amount	Forecast (May 12)	Revised Forecast	Revised Amount	Result	Change(%)	Change
Prescription drugs	183.0	143.5	(39.5)	121.0	106.7	(14.3)	98.8	45.3	44.7
Overseas subsidiaries/export	54.9	61.0	6.1	29.2	30.4	1.2	59.1	3.2	1.9
Shionogi Inc. (US)	22.6	27.2	4.6	11.7	13.6	1.9	23.4	16.2	3.8
Shionogi B.V. (EU)	16.9	19.3	2.4	8.6	9.4	0.8	16.8	14.5	2.4
Shionogi China	7.0	5.9	(1.1)	3.5	3.0	(0.5)	8.7	(31.5)	(2.7)
Others	8.4	8.6	0.2	5.4	4.4	(1.0)	10.2	(15.5)	(1.6)
Contract manufacturing	13.2	14.0	0.8	6.7	6.9	0.2	17.3	(18.9)	(3.3)
OTC and quasi-drug	18.5	17.5	(1.0)	9.6	9.6	0.0	16.8	4.1	0.7
Royalty income	257.9	261.5	3.6	129.2	132.2	3.0	244.7	6.9	16.8
HIV franchise	244.8	245.0	0.2	119.0	119.2	0.2	240.4	1.9	4.6
Others	13.1	16.5	3.4	10.2	13.0	2.8	4.3	286.9	12.2
Others	2.5	2.5	-	1.3	1.3	0.0	1.7	48.8	0.8
Total	530.0	500.0	(30.0)	297.0	287.0	(10.0)	438.3	14.1	61.7

Domestic Prescription Drug Revenue

(Unit: B yen)

	FY2025 Forecast Full year			FY2025 Forecast 2H			FY2024	Y on Y	
	Initial Forecast	Revised Forecast	Revised Amount	Forecast (May 12)	Revised Forecast	Revised Amount	Result	Change(%)	Change
Acute Respiratory Virus Infection Treatments	85.8	56.0	(29.8)	54.8	47.3	(7.5)	51.8	8.1	4.2
Quviviq	9.3	2.5	(6.8)	8.1	2.1	(6.0)	0.8	213.9	1.7
Symproic	8.1	6.5	(1.6)	4.2	3.5	(0.7)	5.0	28.7	1.4
OxyContin franchise	5.6	5.3	(0.3)	2.7	3.0	0.3	4.3	25.1	1.1
Others	74.2	73.2	(1.0)	51.2	50.7	(0.5)	36.9	98.4	36.3
Torii Pharmaceutical	33.0	41.2	8.2	30.0	35.7	5.7	-	-	41.2
Prescription drugs	183.0	143.5	(39.5)	121.0	106.7	(14.3)	98.8	45.3	44.7

Acute respiratory virus infection treatments

- COVID-19 related product: Xocova
- Influenza franchise: Xofluza, Rapiacta

Domestic and Overseas Business Outlook



SHIONOGI

Infectious Disease Policy

Achieving both social contribution and revenue stability by having multiple infectious disease treatments

- COVID-19 treatment -

XOCOVA

(3CL protease inhibitor)



**Oral medications recommended
by academic conference,
regardless of risk of severe
illness*¹**

- Influenza treatments -

XOFLUZA

(Cap-dependent endonuclease inhibitor)


Granules scheduled for release within the year



**The only oral drug that can
treat or prevent disease with a
single dose**

RAPIACTA

(Neuraminidase inhibitor)



**Reliable administration is expected
even when oral is limited**

※Influenza: Trending in the 2025/2026 season (The second fastest in the past 20 years)

Review of our Efforts against COVID-19

While no significant change in overall treatment rates, there was a significant increase in treatment rates for HR*¹ patients

—Treatment rate and Xocova share with oral antivirals—

	FY2025 Target	FY2024 1H	FY2025 1H
Average Xocova share	> 65%	Approximately 65%	Approximately 65%
Treatment rate* ² Average value of the most prevalent month	> 20%	13.1%	13.9%
• Maintains a strong market share in the oral antiviral segment • Despite efforts to raise disease awareness, the treatment rate has seen only a modest increase			

—Treatment rate by risk category—

HR patients	29.4 %* ³ (7.1% up Y on Y) The risk of severe disease remains high, and the need for treatment is becoming increasingly recognized
SR* ⁴ patients	7.0 %* ³ (1.6% up Y on Y) Lower need for treatment despite variant changes

*¹ HR (High Risk): Based on information from the Ministry of Health, Labour and Welfare and academic societies, HR is defined as having risk factors for severe disease such as advanced age or underlying conditions *² Created by our company based on JAMDAS data *³ Created by our company based on JAMDAS data (2024) report *⁴ SR(Standard Risk): Define non-HR cases as SR  **SHIONOGI**

Future Initiatives for COVID-19

Strengthening activities to prevent severe disease in HR patients requiring early diagnosis and treatment

—Need for Preventing Severe Disease in HR Patients—

The current treatment rate is insufficient, and the number of hospitalized patients remains high

Number of hospitalized patients*1
Approximately **50** K people

Early diagnosis and treatment at community clinics is critical

—New clinical guideline announced by the 5 Societies—

- 1 **Recommendation for early diagnosis and early treatment**
- 2 **Recommended Xocova as a treatment option for preventing severe disease**

※Published on October 16, 2025

—Enhancing Xocova Information Provision Activities—

Strengthening activities for HR patients aimed at preventing severe disease

1

Clinical Evidence



Real-world evidence on reducing hospital admissions*3 and shortening hospital stays*4 in HR patients

2

Economic & Pharmaceutical Value



Communicate benefits of reducing severe cases and hospitalization

3

Co-Promotion



Collaborate with Trii flu clinics to reinforce early treatment initiatives

*1 Ministry of Health, Labour and Welfare: October 17, 2025 – Situation Report on Novel Coronavirus Infection (COVID-19) *2 <https://nishakyo.or.jp/siryo/covid-sisin.pdf>


*3 Takahiro Takazono et al., Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19

*4 Ryohei Yoshida et al., Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study

QOL Disease Policy

Making QOL disease a business pillar alongside infectious diseases

Drive substantial growth
in the QOL therapeutic area



Torii

Broad product portfolio delivering steady growth

- Allergen immunotherapy: Cedacure etc
- Dermatology: Corectim / Vtama etc

Shionogi

- Growth of Quviviq*¹
(after removal of prescription period restrictions)
 - Co-promotion with Torii Pharmaceutical is planned
- Launch of Zuranolone*²

*¹ Quviviq: Insomnia treatment (dual orexin receptor antagonist, DORA)

*² Zuranolone: Depression treatment (GABAA receptor (γ-aminobutyric acid-gated chloride ion channel) positive allosteric modulator)


For details on Zuranolone, refer to appendix p. 46 and 47

Towards Expanding Quviviq (Insomnia treatment)

Market penetration accelerated with the lifting of prescription period restrictions on December 1st.

Insomnia Market*¹

Market size: Estimated at over ¥100 billion annually
- Growth of DORA*² driving market expansion



Current Status

- Limited prescription duration: Maximum of 14 days per fill*³

Results of Actions

- Maintained MR detailing rank within **Top 3***⁴
- Number of adoptions expanded steadily
 - Accumulated prescription experience and confirmed positive feedback


*¹ Copyright © 2025 IQVIA. Created by our company based on IQVIA JPM April 2020-March 2025 years Reprinted with permission

22 *² Dual Orexin Receptor Antagonist *³ To ensure the safety and efficacy of new drugs, the prescription period is generally limited to a maximum of 14 days per prescription for one year starting from the month following their listing in the National Drug Price List *⁴ Source: Impact Track, INTAGE Healthcare Inc. (covering GP channels from December 2024 to August 2025)

Strengthening QOL Disease by Full Acquisition of Torii Pharmaceutical


Achieved stable growth in both the allergen and dermatology segments

Allergens



- Operating of API Manufacturing Facility for Cedarcure
- Increasing Inventory in Preparation for Lifting of Shipping Restrictions


Dermatology



- Sustained Growth Driven by Expansion of Corectim
- Further Growth Through Early Market Penetration of Vtama*2

Further Growth of Overseas Business

Accelerate growth in Europe and U.S. business, and full-scale expansion of new drug business in China



Toward the Realization of the 2030 Vision




SHIONOGI

HIV Business: Progress in ViiV's HIV Franchise (GSK's Q2 results as of July 30, 2025)

Driving overall growth of the HIV business through expansion of LAI formulations and oral two-drug regimens

ViiV's sales trends*1



YoY increase from the same period

Treatment **Cabenuva** (cabotegravir + rilpivirine)
+ £177M (+42%) Q1 CY2025 result: £635M

Prevention **Apretude** (cabotegravir)
+ £64M (+56%) Q1 CY2025 result: £190M

Treatment **Dovato** (dolutegravir + lamivudine)
+ £191M (+21%) Q1 CY2025 result: £1,225M


Various Clinical Data Supporting the Growth of LAI Products

Multiple reports suggest that cabotegravir formulations are preferred for treatment and prevention

Treatment

VOLITION trial*1,2

A study investigating whether treatment-naïve people choose to switch to Cabenuva after achieving rapid viral suppression with Dovato



Evaluate the rates and drivers for switching from oral 2-drug regimens to LAI

Switching to Cabenuva

Percentage of patients who chose to switch from oral medication to LAI formulations

89 %


Switching drivers

Not having to worry about missing a dose each day **80 %**
Not having to carry medication **68 %**

Prevention

CLARITY trial*3,4

Phase1 study comparing acceptability and tolerability of single dose cabotegravir (CAB-LA) and lenacapavir (LEN) injections



Evaluate the acceptability of injection site reactions 7 days after administration of each drug.

Participants who answered "completely or very acceptable"

CAB-LA **68 %** LEN **48 %**

Percentage of people who preferred CAB-LA after single dose


HIV-negative adults **90 %** Healthcare providers **86 %**

Clinical Evidence for Oral Two-Drug Regimens Uptake

Dovato as a promising option not only for its viral suppression effects but also for its impact on weight

PASO DOBLE trial*1,2

A head-to-head study comparing the two-drug regimen
Dovato with Biktarvy (three-drug regimen)



Primary endpoint	Viral suppression after 96 weeks of treatment (Proportion of patients with HIV-1 RNA levels of ≥ 50 copies/mL, FDA snapshot method, non-inferiority margin 4%)
Key secondary endpoints	Weight gain, BMI change, percentage of subjects with weight gain of 5% or more, etc.

Results

Achieved primary and key secondary endpoints

- Viral load suppression effects after 96 weeks ----- **Non-inferiority**
- Weight gain side effect ----- **Significantly suppressed**

	Dovato	Biktarvy
Virologic failure	0 case	3 cases
Weight change after 96 wk	0.84 kg	2.35 kg
Percentage of participants gaining $\geq 5\%$ of their body weight at wk 96	20.1%	34.8%
Drug-related adverse events	7.6%	13.4%

*1 [ViiV HEALTHCARE ANNOUNCES 96-WEEK DATA REAFFIRMING DOVATO IS AS EFFECTIVE AS BIKTARVY IN MAINTAINING VIROLOGICAL SUPPRESSION OF HIV-1 WITH SIGNIFICANTLY LESS WEIGHT GAIN](#) *2 [NCT04884139](#)

Investment Strategy for Future Growth

**Aiming to expand business in growth areas
through aggressive investment, leveraging abundant cash flow**



Business Investment

Proactive deal promotion

JT Group Pharmaceutical Business M&A
Several other deals in progress

Prerequisites

- Further strengthen SHIONOGI's strengths
- Do not overinvest or buy at high prices



Capital Investment

Build a production system resilient to changes

Reintegration of Shionogi Pharma
Strengthen the global supply chain

Planned

- Update our own factories
- Establish overseas production capabilities



R&D Investment

Strengthen in-house drug discovery capabilities

Reorganization of research structure
(integration with JT)
Progress in development pipeline

In progress

- Enhance speed and quality of drug discovery
- Aggressive investment in development

Reintegration of Shionogi Pharma*1

**As a company dealing with infectious diseases,
we have reaffirmed the importance of building a production system resilient to environmental changes**

-Changes Leading to the Reintegration-

External Environment

- **Sudden fluctuations in demand**
 - Outbreaks of acute infectious diseases, shortages in medical pharmaceuticals supply
- **Rising geopolitical risks**
 - Risks in supply of raw materials and active pharmaceutical ingredients from overseas, rising costs
- **Declining labor population involved in production and quality**

Business Environment

- **Global business expansion, mainly for infectious disease drugs**
 - Cefiderocol, Ensitrelvir
- **Group pharmaceutical business M&A**
 - Torii and JT products, development pipeline

-Future Challenges and Countermeasures-

Accelerating the construction of a unified group production system

Shionogi & Co., Ltd.
(Parent company)

100%

Shionogi Pharma
Co., Ltd.
(Subsidiary)



Scheduled
for April 2027

Shionogi & Co., Ltd.



Reintegrate production
functions within the company

- Building a production system for sudden fluctuations in demand
- Strengthening efforts in cost control and cost reduction
- Retaining and acquiring personnel responsible for production and quality control

Strengthen the Global Supply Chain

Establish manufacturing methods with superior quality and efficiency at in-house factories, and stably supply products globally under any circumstances

- Build a self-led production network -

Centering on in-house factories and Expanding the range of control within the company

1


manufacturing methods at in-house factories



Establish manufacturing methods with superior quality and efficiency

2

Expansion of production sites



Based on established manufacturing methods, expand to 2nd and 3rd sites

- Initiatives toward realization -



Update on our own factory

- Streamlining production and reducing manpower through advanced manufacturing technologies
 - Promotion of continuous manufacturing and DX^{*1} initiatives



Enhancement of overseas manufacturing capabilities

- Establishment of new overseas production sites
- Strengthening the global network with CMOs^{*2} and suppliers



S&OP^{*3} Function Reform

- **Strengthening collaboration among sales, supply, and production function**
 - Providing pharmaceuticals according to infectious disease trends
 - Stable supply based on highly accurate forecasts

Major Development Projects: Infectious Diseases

Project	Indication	Current stage* ¹	Update
Ensitrelvir	COVID-19 treatment	Submission	Acceptance of New Drug Application by the EMA*²
	COVID-19 treatment (age 6-11)	Submission	
	COVID-19 PEP	Submission	Acceptance of New Drug Application by the FDA*³ and EMA
S-268024	COVID-19 (JN.1 vaccine)	Phase 3	
Cefiderocol	AMR* ⁴ (Pediatric • Gram-negative bacteria infection)	Phase 3	Completed submission of all clinical trial reports to the FDA and EMA
Olorofim	Invasive Aspergillosis	Phase 3	
S-337395	RSV infections	Phase 2b	Initiated a phase 2b trial
S-892216	COVID-19 treatment (Oral pill • treatment)	Phase 2	Primary endpoint achieved
	COVID-19 (Long-acting injectable • pre-exposure prophylaxis)	Phase 1	Fast Track designation granted by the FDA
S-743229	AMR (Complicated urinary tract infection)	Phase 1	
S-649228	AMR (Gram-negative bacteria infection)	Phase 1	
S-567123	COVID-19 Prevention(Injection)	non-clinical	

Major Development Projects: QOL Disease with High Social Impact

Project	Indication	Current stage* ¹	Update
Zuranolone	Depression	Submission	
Resiniferatoxin	Pain associated with knee osteoarthritis	Phase 3	
Zatolmilast	Fragile X syndrome	Phase 2/3	LPO*² achieved
	Jordan syndrome	Phase 2	
Redasemtide	Dystrophic epidermolysis bullosa	Phase 2	
	Acute ischemic stroke	Phase 2b	
SASS-001 (S-600918+ Combination medicine)	Sleep apnea syndrome (central component)	Phase 2	
SASS-002 (Sulthiame)	Sleep apnea syndrome (obstructive)	Phase 2	The results of the Phase 2 trial were published in the Lancet*³
S-606001	Pompe disease	Phase 2	
S-309309	Obesity	Phase 2	
S-531011	Solid tumors	Phase 1b/2	Obtained the results of Phase 1b parts
S-151128	Chronic pain	Phase 1b	

*¹ The current stage indicated refers to the most advanced stage in any region, excluding countries or regions where the product has already been launched, and is not based on any specific region

*² LPO : Last Patient Out *³ The clinical trial conducted by Desitin prior to asset introduction to Shionogi-Apnimed Sleep Science, LLC: [The Lancet](#)

S-892216 (COVID-19 Treatment, Oral): Phase 2 Trial Results

The Phase 2 trial conducted in Japan and US successfully achieved its primary endpoint

Trial design

Trial Design	Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group trial
Subjects	Outpatients with COVID-19
Primary Endpoint	Change from baseline in SARS-CoV-2 viral RNA level by qRT-PCR testing (Nasopharyngeal swabs) on day 4
Secondary Endpoints	Safety, Pharmacokinetics, Time to sustained resolution of COVID-19 symptoms etc.
Dosing Regimen Sample Size	70 subjects each group • Placebo • S-892216: 3 groups

Preliminary trial results

- **Achieved primary endpoint**
 - Statistically significant reductions in viral load were confirmed in all S-892216 groups compared with placebo
- No new safety concerns were identified



Accelerating data analysis and study design planning in preparation for the upcoming Phase 3 trials

Cefiderocol Development Progress

**Positive results confirmed in clinical trials on pediatric and neonates,
application to be filed in Europe and the US within the fiscal year**

Trial overview

Trial list

Pediatric*¹: PEDI-CEFI*², APEKS-PEDI*³
Neonate*⁴: NEO-CEFI*⁵


Study population

Hospitalized pediatric and neonatal patients with suspected or confirmed aerobic gram-negative bacterial infections

objective

Evaluate safety, tolerability, and pharmacokinetics in single and multiple doses

Results




- **Confirmed safety equivalent to that of adults**
- **Confirmed maintenance of plasma concentrations at therapeutically effective levels**

S-531011 Mechanism and Future Schedule

Phase 1b trials showed positive results, and Phase 2 trials are currently underway

Concept and Mechanism


- 1995: Discovery of the existence of Treg*1
- 2014: Collaborative research with Osaka University on Treg begins
- 2018: CCR8*2, which is selectively highly expressed in intratumoral Tregs (patent pending) is discovered
- 2022: Clinical trials for S-531011 (a humanized antibody targeting CCR8) begins



- 1 S-531011 selectively binds to CCR8 expressed on tumor-infiltrating Tregs, exhibiting ADCC*3 activity, ADPC*4 activity, and neutralizing activity
- 2 Depletes tumor-infiltrating Tregs, thereby relieving immunosuppression
- 3 Restores tumor immunity and exerts antitumor effects

Phase 1b trial results*5 and future schedule

- Both monotherapy and combination therapy with pembrolizumab demonstrated **promising antitumor activity in advanced and metastatic colorectal cancer**
- All doses were **well tolerated**, both as monotherapy and in combination with Pembrolizumab



*1 CCR8: Chemokine (C-C motif) receptor 8 *2 Treg: Regulatory T cell *3 ADCC: Antibody-Dependent Cellular Cytotoxicity *4 ADPC: Antibody-Dependent Cellular Phagocytosis *5 Presented at ASCO 2025 (American Society of Clinical Oncology Annual Meeting)

Shareholder Return




SHIONOGI

Shareholder Returns

Shareholder return policy through which shareholders can feel our growth

- Considering flexible share buybacks based on the progress of growth investments
- Planning for the **14th** consecutive annual dividend increase in FY2025
- End of second quarter dividend: ¥33*¹



*¹ Effective October 1, 2024, Shionogi has implemented a 3-for-1 stock split of its common stock. Dividends and Treasury stock's Cancellation are calculated based on the assumption that the stock split was implemented at the beginning of the FY2012 *² Resolution passed on March 30, 2020, and treasury shares cancelled on April 6

*³ Resolution passed on July 31, 2023, and treasury shares cancelled on April 17, 2024

Appendix

Shareholder Returns

Financial KPIs for the Medium-Term Management Plan STS2030 Revision Phase 2*1

Shareholder returns	FY2023 Results	FY2024 Results	FY2025 Goal
EPS	181.17 yen	200.36 yen	200 yen or more
DOE	4.0 %	4.0 %	4 %
ROE	13.9 %	13.1 %	14 % or more

FY2025 Exchange Rate

Exchange rate (average during the period)

	FY2025		
	Forecast (5/13)	Forecast (10/27)	Apr.-Sep. Results
USD(\$) – JPY(¥)	147 yen	146 yen	146.03 yen
GBP(£) – JPY(¥)	187 yen	197 yen	195.96 yen
EUR(€) – JPY(¥)	153 yen	171 yen	168.06 yen

Major Development Products

- Infection Diseases -

Pipeline	Indication	Current stage	Target Launch Timing*1
Ensitrelvir	COVID-19 treatment	Submission	- FY2027
	COVID-19 treatment (Pediatric Ages 6-11)	Submission	- FY2027
	COVID-19 PEP	Submission	- FY2027
S-268024	COVID-19 (JN.1Vaccine)	Phase3	- FY2027
Cefiderocol	Pediatric, Gram-negative bacteria infection	Phase 3	- FY2027
Olorofim	Invasive Aspergillosis	Phase 3	FY2028-2030
S-337395	RSV infections	Phase 2	FY2028-2030
S-743229	Complicated urinary tract infection	Phase 1	FY2028-2030
S-649228	Gram-negative bacteria infection	Phase 1	FY2028-2030
S-567123	COVID-19 (Universal vaccine)	Preclinical	FY2028-2030
S-892216	COVID-19 treatment (Oral))	Phase 2	FY2028-2030
	COVID-19 Prevention (Injection)	Phase 1	FY2031-

- QOL Diseases -

Pipeline	Indication	Current stage	Target Launch Timing*1
Zuranolone	Depression	Submission	FY2025
Resiniferatoxin	Pain associated with knee osteoarthritis	Phase 3	- FY2027
Zatolmilast	Fragile X syndrome	Phase 2/3	- FY2027
	Jordan syndrome	Phase 2	- FY2027
Redasemtide	Dystrophic epidermolysis bullosa	Phase 2	- FY2027
	Acute ischemic stroke	Phase 2b	FY2028-2030
SASS-001 (S-600918 + Combination medicine)	Sleep Apnea with a Central Component	Phase 2	FY2028-2030
S-531011	Solid tumor	Phase 1b/2	FY2028-2030
S-151128	Chronic pain	Phase 1b	FY2031-
S-606001	Pompe disease	Phase 2	FY2031-
S-309309	Obesity	Phase 2	Development Plan Under Consideration

R&D Milestones Planned for FY2025


Red: Update from July 29, 2025, to October 28, 2025, ✓: Milestone-completed items

※Topline results: It is the timing of acquisition, and the timing of disclosure will be considered separately

Disease area	Pipeline	Indication	Current stage	FY2025 1H		FY2025 2H	
Infection Diseases	Ensitrelvir	COVID-19 treatment	Submission	Submission (EU)	✓		
		COVID-19 PEP	Submission	Submission (US, EU)	✓	Approval (Japan)	
		COVID-19 treatment (Pediatric Ages 6-11)	Submission	Submission (Japan)	✓		
	S-268024	COVID-19 (JN.1Vaccine)	Phase 3	Phase 3 Topline results	✓		
	Cefiderocol	Pediatric, Gram-negative bacteria infection	Phase 3	Phase 3 Topline results	✓	Submission (US, EU)	
	S-892216	COVID-19 treatment (Oral)	Phase 2			Phase 2 Topline results	✓
	S-743229	complicated urinary tract infection	Phase 1			Phase 1 Topline results	
	S-649228	Gram-negative bacteria infection	Phase 1			Phase 1 Topline results	
QOL Diseases with High Social Impact	Zuranolone	Depression	Submission			Approval (Japan)	
	Zatolmilast	Fragile X syndrome	Phase 2/3			Phase 2/3 Topline results	
	SASS-001 (S-600918 + Combination medicine)	Sleep Apnea with a Central Component	Phase 2			Phase 2 Topline results	
	S-531011	Solid tumor	Phase 1b/2			Phase 2 Topline results	
	S-606001	Pompe disease	Phase 2	Phase 1 Topline results	✓		
	S-740792	Gait disorders associated with multiple sclerosis	Phase 1			Phase 1 Topline results	

Pipeline: Infectious Disease

as of October 27, 2025




Change from July 29, 2025, to October 27, 2025

- Baloxavir (Influenza virus infection Granules, < 20kg): Approval in Japan

Pipeline: QOL Diseases with High Social Impact

as of October 27, 2025



Change from July 29, 2025, to October 27, 2025

- YCANTH*1: Approval in Japan
- Tapinarof *1 (Atopic dermatitis in Pediatric Patients): Submission in Japan
- Tapinarof *1 (Atopic dermatitis in infants): Phase 3
- TO-210*1: Phase 3
- TO-209*1: Phase 3
- TO-203*1: Phase 3
- Cantharidin*1: Phase 2*2


: Progress from to July 29 2025, to October 27, 2025

Out license

Zuranolone: New Drug Application (NDA) in Japan for Major Depressive Disorder


Based on favorable clinical trial results, submitted NDA in Japan*

Results from Phase 3 validation study



Achieved the primary endpoint and confirmed the rapid onset of action of zuranolone


Primary endpoint: Change from baseline in the total HAM-D17 score*² on Day 15
Response rate: The percentage of patients whose total HAM-D score*² improved by 50% or more from baseline
Overview of the Phase 3 validation study design: [Please refer to appendix p.47](#)



Observed favorable results in the response rate, a measure of antidepressant efficacy

Zuranolone: Phase 3 Validation Study Design


Subject	Patients with moderate to severe major depressive disorder
Purpose	[Part A] Examination of superiority of Zuranolone over placebo [Part B] Examination of safety and tolerability of re-administration when necessary
Primary endpoint	Change from baseline in the total HAM-D17 score on Day 15
Dosing group	[Part A] A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial [Part B] Multicenter, open label
Sample size	Zuranolone 30mg group, placebo group
Dose administration	[Targets] 200 in each group, 400 in total, [Result] 412



S-337395*1: Upcoming Development Plan (Phase 2b trial overview and design)

Initiated a Phase 2b study targeting high-risk patients, aiming to develop the world's first oral therapeutic

Primary Endpoint	Change from baseline in viral RNA load (qRT-PCR)
Secondary objectives	Efficacy assessment: time-course change from baseline in symptom severity score
Trial Design	Multicenter, randomized, double-blind, placebo-controlled, parallel-group design
Dosing Regimen Sample Size	- Randomization cohorts: placebo (n=64) - S-337395 low dose (n=64), high dose (n=64)




Anti-HIV Drug Released by ViiV

Product name	Formulations	Compounds	Administrations	Frequency	Indications	CY2024 Sales
Cabenuva	LAI formulations	CAB + RPV	IM injection	Q2M (LA)	Treatment	£ 1,013M
Apretude		CAB	IM injection	Q2M (LA)	PrEP	£ 279M
Dovato	Oral two-drug regimens	DTG + 3TC	Oral	Every day	Treatment	£ 2,239M
Juluca		DTG + RPV	Oral	Every day	Treatment	£ 685M
Tivicay	Oral single agent	DTG	Oral	Every day	Treatment	£ 1,350M
Triumeq	Oral three-drug regimen	DTG+ABC+3TC	Oral	Every day	Treatment	£ 1,325M

Growth Outlook for the HIV Market (Treatment + Prevention)

In the treatment and PrEP*¹ market, LA formulations will continue to drive growth

Outlook for the HIV Market*² (Treatment + PrEP)



The core of the HIV market will continue to be the **treatment market**

// Treatment

- In the US, new infections have increased by approximately 2.5-3% in recent years*³
- The market size will be stable even after the launch of oral GE drugs
- **LA formulations, including integrase inhibitors**, will continue to be mainstream
 - LA injectables are expected to represent approximately **~30%** of the total by 2031

// PrEP

- In the US, currently about one-third of potential candidates (approximately 1.2 million people) are receiving PrEP medications*⁴
- With the penetration of LA formulations, the overall PrEP market is expected to expand
 - LA injectables are expected to represent approximately **~80%** of the total by 2031
- LA integrase inhibitors are also expected to be an important option in the PrEP market, potentially taking over the substantial majority of the market if reimbursement is sufficient.

Other Major Progress^{*1}

- August

- Shionogi & Co., Ltd. Selected for METI's FY2024 Supplementary Budget Grant Program for Future-Oriented Co-Creation with the Global South – Feasibility Study on the Use of Digital Solutions to Promote Appropriate Use of Japan-Origin Antimicrobials and Hygiene Products in Kenyan Healthcare Facilities –

- September

- Shionogi & Co., Ltd. and FRONTEO launch "Talk Lab KIBIT," a web application that uses AI analysis to assess mental health.
- Shionogi & Co., Ltd. and FRONTEO have signed an absorption-type company split agreement to transfer Japan Tobacco Inc.'s pharmaceutical business to Shionogi.
- Shionogi & Co., Ltd. and AirDog Japan have signed a basic business agreement to promote awareness of the current state and challenges of infectious diseases.

Forward-Looking Statements

- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.